In 1954, Sigma Kappa became the first sorority to recognize the need for continued comprehensive work on the study of aging and the needs of the elderly population after adopting gerontology as its second national philanthropy; and in 1984, in response to an increasingly critical problem facing older Americans, an emphasis on Alzheimer’s disease was added.
Sigma Kappa Foundation is committed to providing major funding for Alzheimer’s disease research as a national partner of the Alzheimer’s Association. Our ideal project funding scenario is a female researcher working on a campus with an active Sigma Kappa chapter. Read the final report from the latest funded research.
Since 1989, the Foundation has provided nearly $3 million for Alzheimer’s disease prevention, research and treatment efforts.
Sigma Kappa Foundation Makes $1 Million Commitment to Alzheimer’s Association
Sigma Kappa Foundation has announced that it will provide the lead gift of $1 million for the Alzheimer’s Association Women’s Research Initiative, funding clinical research focused on women, as well as studies led by female researchers who are working to advance Alzheimer’s and dementia science.
Carolyn Caudell Tieger, Epsilon Epsilon, University of Georgia, has called for Sigma Kappa to raise $500,000 by Convention July 2016 and she will match it dollar for dollar, allowing our sorority to achieve our commitment in two years instead of five. Read the full press release.
Walk to End Alzheimer’s®
Sigma Kappa members are encouraged to participate in the Alzheimer’s Association annual Walk to End Alzheimer’s®. The Sigma Kappa Foundation participates as national gold team with a goal of 100 teams raising $200,000.
Walk to End Alzheimer’s is more than a walk; it’s the nation’s largest event to raise awareness and funds for Alzheimer’s care, support and research. It is an inspiring experience that calls participants to unite in a movement to reclaim the future for millions. Participants will learn about Alzheimer’s disease and how to get involved with this critical cause, from advocacy opportunities, the latest in Alzheimer’s research and clinical trials and support programs and services.